BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014;10:1297-307. [PMID: 25075188 DOI: 10.2147/NDT.S41387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat 2019;15:1249-58. [PMID: 31190831 DOI: 10.2147/NDT.S199746] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
2 Borroto-Escuela DO, Narváez M, Ambrogini P, Ferraro L, Brito I, Romero-Fernandez W, Andrade-Talavera Y, Flores-Burgess A, Millon C, Gago B, Narvaez JA, Odagaki Y, Palkovits M, Diaz-Cabiale Z, Fuxe K. Receptor⁻Receptor Interactions in Multiple 5-HT1A Heteroreceptor Complexes in Raphe-Hippocampal 5-HT Transmission and Their Relevance for Depression and Its Treatment. Molecules 2018;23:E1341. [PMID: 29865267 DOI: 10.3390/molecules23061341] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
3 Yoshimura R, Ikenouchi A, Okamoto N, Konishi Y. A Case of Major Depression with Burning Mouth Syndrome and Tinnitus Successfully Treated with Vortioxetine. Int Med Case Rep J 2021;14:271-3. [PMID: 33953617 DOI: 10.2147/IMCRJ.S306154] [Reference Citation Analysis]
4 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
5 Carta MG, Pala AN, Finco G, Musu M, Moro MF. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health 2015;11:144-9. [PMID: 25893002 DOI: 10.2174/1745017901511010144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
6 Pehrson AL, Sanchez C. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Des Devel Ther 2015;9:603-24. [PMID: 25653499 DOI: 10.2147/DDDT.S62912] [Cited by in Crossref: 88] [Cited by in F6Publishing: 40] [Article Influence: 14.7] [Reference Citation Analysis]
7 Yoshimura R, Okamoto N, Konishi Y, Ikenouchi A. Major depression with musical obsession treated with vortioxetine: a case report. Ann Gen Psychiatry 2021;20:19. [PMID: 33750381 DOI: 10.1186/s12991-021-00340-8] [Reference Citation Analysis]
8 El Mansari M, Lecours M, Blier P. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology (Berl) 2015;232:2343-52. [PMID: 25665528 DOI: 10.1007/s00213-015-3870-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
9 Zuena AR, Maftei D, Alemà GS, Dal Moro F, Lattanzi R, Casolini P, Nicoletti F. Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Mol Pain 2018;14:1744806918808987. [PMID: 30289053 DOI: 10.1177/1744806918808987] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
10 Özdemir A, Altıntop MD, Kaplancıklı ZA, Can ÖD, Demir Özkay Ü, Turan-Zitouni G. Synthesis and evaluation of new 1,5-diaryl-3-[4-(methyl-sulfonyl)phenyl]-4,5-dihydro-1H-pyrazole derivatives as potential antidepressant agents. Molecules 2015;20:2668-84. [PMID: 25658142 DOI: 10.3390/molecules20022668] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
11 Urade CS, Mahakalkar SM, Tiple PG. A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: A randomized, parallel-group, phase IV study. J Pharmacol Pharmacother 2015;6:198-203. [PMID: 26813706 DOI: 10.4103/0976-500X.171883] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
12 Sexton JD, Nichols CD, Hendricks PS. Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics. Front Psychiatry 2019;10:896. [PMID: 32116806 DOI: 10.3389/fpsyt.2019.00896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]